0A55.L - QuidelOrtho Corporation
| Previous close | 88.25 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 242 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | 0.04 |
| EPS (TTM) | 23.62 |
| Earnings date | 02 May 2023 - 08 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireQuidelOrtho to Participate in William Blair 43rd Annual Growth Stock Conference
SAN DIEGO, May 23, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the William Blair 43rd Annual Growth Stock Conference in Chicago, Illinois, on June 6, 2023.
Business WireQuidelOrtho Reports First Quarter 2023 Financial Results
SAN DIEGO, May 03, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the first quarter ended April 2, 2023.
Business WireQuidelOrtho Reports Preliminary Revenue Results for the First Quarter 2023
SAN DIEGO, April 13, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary revenue results for the first quarter ended April 2, 2023.
Business WireQuidelOrtho Announces the Formation of the International QuidelOrtho Women’s Leadership Network (QWLN)
SAN DIEGO, March 28, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, celebrates Women’s History Month by announcing that the QuidelOrtho Women’s Leadership Network (QWLN) has been formed, creating an enhanced network with 14 global leaders supporting 16 chapters around the world.
Simply Wall St.QuidelOrtho Corporation (NASDAQ:QDEL) Shares Could Be 36% Below Their Intrinsic Value Estimate
Key Insights QuidelOrtho's estimated fair value is US$137 based on 2 Stage Free Cash Flow to Equity QuidelOrtho's...
Zacks3 Reasons to Retain QuidelOrtho (QDEL) Stock in Your Portfolio
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
- Zacks
QuidelOrtho's (QDEL) Rapid Antigen Test Gets De Novo FDA Approval
QuidelOrtho's (QDEL) receipt of the FDA's De Novo approval is expected to enable it to provide the test as an aid in the diagnosis of SARS-CoV-2 infections in symptomatic individuals.
Business WireQuidelOrtho Receives De Novo FDA Authorization for Sofia® 2 SARS Antigen+ FIA
SAN DIEGO, March 08, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted a De Novo request from the U.S. Food and Drug Administration (FDA), allowing the company to market its new Sofia® 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+ FIA is the first rapid antigen test that detects COVID-19 to be awarded F
Business WireQuidelOrtho to Participate in the Raymond James 44th Annual Institutional Investor Conference
SAN DIEGO, March 02, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference in Orlando, Florida, on March 7, 2023.
- Simply Wall St.
QuidelOrtho Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag
QuidelOrtho ( NASDAQ:QDEL ) Full Year 2022 Results Key Financial Results Revenue: US$3.27b (up 92% from FY 2021). Net...
- Simply Wall St.
QuidelOrtho Corporation Just Missed Revenue By 8.0%: Here's What Analysts Think Will Happen Next
It's been a good week for QuidelOrtho Corporation ( NASDAQ:QDEL ) shareholders, because the company has just released...
ZacksQuidelOrtho (QDEL) Q4 Earnings Top Estimates, Margins Down
QuidelOrtho (QDEL) reports robust overall top-line results in fourth-quarter 2022, despite disappointing segmental and geographical performances on a reported basis.
Business WireQuidelOrtho Reports Fourth Quarter and Full Year 2022 Financial Results
SAN DIEGO, February 15, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the fourth quarter ended January 1, 2023.
- Simply Wall St.
QuidelOrtho (NASDAQ:QDEL) pulls back 4.3% this week, but still delivers shareholders favorable 14% CAGR over 5 years
Stock pickers are generally looking for stocks that will outperform the broader market. Buying under-rated businesses...
Business WireQuidelOrtho Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022
SAN DIEGO, January 06, 2023--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary unaudited revenue results for the fourth quarter and full year ended January 1, 2023.
- Simply Wall St.
Is QuidelOrtho Corporation's (NASDAQ:QDEL) Latest Stock Performance A Reflection Of Its Financial Health?
QuidelOrtho (NASDAQ:QDEL) has had a great run on the share market with its stock up by a significant 19% over the last...
Business WireQuidelOrtho to Present at the J.P. Morgan Healthcare Conference
SAN DIEGO, December 28, 2022--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco beginning on January 9, 2023, with a presentation scheduled for 9:00 a.m. PST / 12:00 p.m. EST.
ZacksQuidelOrtho's (QDEL) Myocardial Infarction Test Cleared in Canada
QuidelOrtho's (QDEL) TriageTrue hsTnl Test is to be used to diagnose myocardial infarction following Health Canada's approval.
Business WireHealth Canada Grants License for Quidel® TriageTrue® High-Sensitivity Troponin I Test to Aid in the Diagnosis of Myocardial Infarction
SAN DIEGO, December 19, 2022--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that Health Canada has approved for use in Canada the Quidel TriageTrue High-Sensitivity Troponin I (hsTnl) Test on the Quidel Triage® MeterPro®, a high-performance, comprehensive testing platform with the smallest footprint analyzer, to aid in the diagnos
Business WireQuidelOrtho and Runda Medical Form Joint Venture to Develop and Manufacture Assays for VITROS® Platform
SAN DIEGO, December 16, 2022--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho" or the "Company"), a global provider of innovative in vitro diagnostics (IVD) technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the signing of a definitive agreement to form a joint venture (JV) between Ortho Clinical Diagnostics Trading (China) Co., Ltd., a subsidiary of QuidelOrtho, and Shanghai Medconn Biotechnology Co., Ltd., a subsidiary of Shanghai Run
Business WireQuidelOrtho Announces Separation of Chairman and Chief Executive Officer Roles
SAN DIEGO, December 12, 2022--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho" or the "Company"), a global provider of innovative in vitro diagnostic (IVD) technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that its Board of Directors (the "Board") has appointed Dr. Kenneth F. Buechler, Lead Independent Director, to non-executive Chairman, effective December 11, 2022. The separation of the Chairman and Chief Executive Officer roles is a
- Business Wire
QuidelOrtho to Host Investor Day on December 13, 2022
SAN DIEGO, November 30, 2022--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will host an Investor Day on Tuesday, December 13, 2022, starting at 1:00 p.m. ET / 10:00 a.m. PT at Convene at Nasdaq MarketSite, 151 West 42nd Street, New York, NY 10036.
Motley FoolWhy QuidelOrtho Stock Slipped and Fell Today
Investors traded out of the shares in the wake of a quarterly report that showed a notable fall on the bottom line.
- Business Wire
QuidelOrtho Reports Third Quarter 2022 Financial Results
SAN DIEGO, November 02, 2022--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the third quarter ended October 2, 2022.
- Simply Wall St.
Are Investors Undervaluing QuidelOrtho Corporation (NASDAQ:QDEL) By 49%?
In this article we are going to estimate the intrinsic value of QuidelOrtho Corporation ( NASDAQ:QDEL ) by taking the...